Abstract:Our appreciation of mitochondrial disease, in the context of both genetic and phenotypic heterogeneity, has blossomed over recent years with successive epidemiological studies, accrued clinical expertise and scientific advances. Epidemiological studies have encountered numerous obstacles, most importantly the initial recognition and diagnosis of a rare and variable multisystem disorder, but also complex referral pathways, specific and evolving diagnostic techniques, impaired penetrance and heteroplasmic mtDNA mutations, and the potential for ascertainment bias in disease cohorts. These inherent difficulties have contributed to both historical over- and under-representation of specific mtDNA or nuclear DNA-related mitochondrial disease. The last three decades have seen over 250 pathogenic mtDNA mutations identified, and the evolution of whole-genome sequencing is now identifying increasing numbers of pathogenic nuclear disease genes. Only recently has it been possible to estimate the prevalence of disease due to mutations of both the nuclear and mitochondrial genomes. To date, the most detailed prevalence figures available report the number of adults suffering from all forms of mitochondrial disease to be in the region of 12.5 per 100,000 of the population. One in 4300 people (23 per 100,000) carry pathogenic mutations of either nuclear or mtDNA and either have disease or are at risk of disease in the future. The most prevalent single mutation to cause mitochondrial disease is now recognised to be due to the m.3243A>G mutation in the MT-TL1 gene with a disease estimation of 3.5 per 100,000. Childhood-onset mitochondrial disease has been predicted to range from 0.5 to 1.5 cases per 100,000, approximately one-tenth of that seen in adults. Although no true population-based prevalence studies have yet been performed using laborious whole-genome sequencing, most existing studies focus on screening for individual mutations within cohorts felt to represent either the general population or the particular disease-defined cohorts. A small number of specific mtDNA mutations have been identified as causing a proportion of disease in diabetes, deafness and optic neuropathy cohorts. Although often considered a hallmark of mitochondrial disease, the prevalence of diabetes in most forms of mitochondrial disease is no higher than 10–12% as compared with a prevalence in the general population of 4.5%. The recognised association can be mainly attributed to the prevalent m.3243A>G mutation which frequently presents with maternally inherited deafness and diabetes. Deafness is common among many mtDNA mutations, usually as part of a broader phenotype, but can be the sole manifestation in the m.1555A>G mutation, particularly following exposure to aminoglycoside antibiotics. Leber’s hereditary optic neuropathy (LHON) occurs as a result of three common mutations in 90% of affected patients, with the point prevalence of disease standing at 3.7 per 100,000.The provision and development of highly specialised services, prospective cohort studies and use of objective clinical rating scales have contributed heavily to our understanding of the mitochondrial disorders today, and are likely to be instrumental in achieving more accurate epidemiological studies in mitochondrial disease in the future.

Mitochondrial diseases in adults

Nuclear Genes and Mitochondrial Genes Associated with Mitochondrial Diseases

Therapeutic and tampering approaches for mitochondrial associated diseases

Mitochondrial functional defects and the disorders in the nervous system

A Clinical-Pathophysiological Perspective

Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease

Epidemiology of Mitochondrial Disease

Current and Emerging Clinical Treatment in Mitochondrial Disease

Mitochondrion and Its Related Disorders: Making a Comeback

Personalized Medicine in Mitochondrial Health and Disease: Molecular Basis of Therapeutic Approaches Based on Nutritional Supplements and Their Analogs

Recent advances in understanding the molecular genetic basis of mitochondrial disease

Genetics of mitochondrial diseases: Current approaches for the molecular diagnosis

Skeletal Phenotypes Due to Abnormalities in Mitochondrial Protein Homeostasis and Import

Endocrine Manifestations and New Developments in Mitochondrial Disease

Therapeutic Approaches to Treat Mitochondrial Diseases: “One-Size-Fits-All” and “Precision Medicine” Strategies

Mitochondrial Diseases: Hope for the Future

A Review over Mitochondrial Diseases Due to mtDNA Mutations: Recent Advances and Remedial Aspects

[Diseases caused by mitochondrial dysfunction]

Challenges and opportunities to bridge translational to clinical research for personalized mitochondrial medicine

Mitochondrial Parkinsonism: A Practical Guide to Genes and Clinical Diagnosis

Enhanced mitochondrial genome analysis: bioinformatic and long-read sequencing advances and their diagnostic implications